scholarly journals Pitfalls of viral load testing

2010 ◽  
Vol 31 (3) ◽  
pp. 119
Author(s):  
Geoff Higgins

Viral load testing is the quantitative measurement of viral nucleic acid in body fluids or tissues. In medical practice, viral load assays are commonly performed for HIV, Hepatitis B and Hepatitis C viruses. These assays are funded under the Medicare Benefits Schedule (MBS) system (Item numbers 69378/81/82, 69482/3 and 69488 respectively).

Author(s):  
AP Okwuraiwe ◽  
OB Salu ◽  
CK Onwuamah ◽  
OS Amoo ◽  
NN Odunukwe ◽  
...  

2018 ◽  
Vol 251 ◽  
pp. 75-79 ◽  
Author(s):  
Emilande Guichet ◽  
Laetitia Serrano ◽  
Christian Laurent ◽  
Sabrina Eymard-Duvernay ◽  
Christopher Kuaban ◽  
...  

2020 ◽  
Vol 73 ◽  
pp. S838-S839
Author(s):  
Joan Martinez ◽  
Ariadna Rando ◽  
Fernando Velasquez ◽  
Mar Riveiro Barciela ◽  
Paula Salmerón ◽  
...  

2018 ◽  
Vol 90 (8) ◽  
pp. 1423-1426 ◽  
Author(s):  
Michael Payne ◽  
Linda Merrick ◽  
Tanya Lawson ◽  
Gordon Ritchie ◽  
Christopher Lowe

2014 ◽  
Vol 155 (26) ◽  
pp. 1019-1023
Author(s):  
Judit Gervain

The successful therapy of hepatitis C viral infection requires that the illness is diagnosed before the development of structural changes of the liver. Testing is stepwise consisting of screening, diagnosis, and anti-viral therapy follow-up. For these steps there are different biochemical, serological, histological and molecular biological methods available. For screening, alanine aminotransferase and anti-HCV tests are used. The diagnosis of infection is confirmed using real-time polymerase chain reaction of the viral nucleic acid. Before initiation of the therapy liver biopsy is recommended to determine the level of structural changes in the liver. Alternatively, transient elastography or blood biomarkers may be also used for this purpose. Differential diagnosis should exclude the co-existence of other viral infections and chronic hepatitis due to other origin, with special attention to the presence of autoantibodies. The outcome of the antiviral therapy and the length of treatment are mainly determined by the viral genotype. In Hungary, most patients are infected with genotype 1, subtype b. The polymorphism type that occurs in the single nucleotide located next to the interleukin 28B region in chromosome 19 and the viral polymorphism type Q80K for infection with HCV 1a serve as predictive therapeutic markers. The follow-up of therapy is based on the quantitative determination of viral nucleic acid according to national and international protocols and should use the same method and laboratory throughout the treatment of an individual patient. Orv. Hetil., 2014, 155(26), 1019–1023.


Sign in / Sign up

Export Citation Format

Share Document